Background-Soluble stem cell factor (SCF) has been shown to mobilize bone marrow stem cells and improve cardiac repair after myocardial infarction (MI). However, the effect of membrane-associated SCF on cardiac remodeling after MI is not known. The present study investigated the effects of cardiomyocyte-specific overexpression of the membrane-associated isoform of human SCF (hSCF) on cardiac function after MI. Methods and Results-A novel mouse model with tetracycline-inducible and cardiac-specific overexpression of membrane-associated hSCF was generated. MI was induced by left coronary artery ligation. Thirty-day mortality after MI was decreased in hSCF/tetracycline transactivator (tTA) compared with wild-type mice. In vivo cardiac function was significantly improved in hSCF/tTA mice at 5 and 30 days after MI compared with wild-type mice. Endothelial progenitor cell recruitment and capillary density were increased and myocardial apoptosis was decreased in the peri-infarct area of hSCF/tTA mice. Myocyte size was decreased in hSCF/tTA mice 30 days after MI compared with WT mice. Furthermore, hSCF overexpression promoted de novo angiogenesis as assessed by matrigel implantation into the left ventricular myocardium. Conclusions-Cardiomyocyte-specific overexpression of hSCF improves myocardial function and survival after MI.
M yocardial infarction (MI) is responsible for about one third of heart failure cases and causes Ϸ2 million deaths per year worldwide. 1 MI leads to scar formation and subsequent ventricular remodeling, which is characterized by infarct expansion, progressive fibrous replacement of myocardium, hypertrophic growth of the noninfarct myocardium, and left ventricular (LV) dilatation. Cardiac remodeling contributes to the development of heart failure after MI. 2 Despite optimal pharmacological treatment, the prognosis of heart failure remains poor. 3 
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Stem cell factor (SCF), also known as Steel factor, mast cell growth factor, or c-kit ligand, binds to its receptor c-kit and promotes survival, proliferation, mobilization, and adhesion of all c-kit-expressing cells, which includes hematopoi-etic stem cells, endothelial progenitor cells, 4, 5 and cardiac stem cells. 6 SCF is expressed as a glycosylated transmembrane protein by many cells and tissues, including stromal cells, fibroblasts, endothelium, and myocardium. 7, 8 Alternative splicing leads to 2 isoforms of SCF: soluble and membrane-associated (SCF) isoforms, which differ in the absence or presence of a proteolytic cleavage site encoded by exon 6. Soluble SCF and membrane-associated SCF have distinct but overlapping roles. Membrane-associated SCF, the dominant isoform in vivo, induces a more persistent receptor activation and is more effective at promoting long-term support of target cell survival. 9 Transgene expression of membrane-associated SCF in Steel-dickie (sld) mutant mice resulted in a significant relief from anemia and bone marrow hypoplasia. 10 In contrast, overexpression of the full-length soluble form of the SCF transgene had no effect on red blood cell production but corrected the myeloid progenitor cell deficiency seen in these mutants. 10 Recently, treatment with soluble SCF in combination with granulocyte-colony stimulating factor improved cardiac repair and survival after MI, whereas soluble SCF treatment alone did not. 11 Because the membrane-associated SCF has a much different biological profile compared with soluble SCF, it is possible that cardiacspecific overexpression of membrane-associated SCF may promote cardiac repair mechanisms after MI.
We hypothesized that inducible cardiomyocyte-specific overexpression of membrane-associated human SCF (hSCF) could improve cardiac repair, myocardial function, and survival after MI. To test this hypothesis, we generated a novel transgenic mouse that overexpresses membrane-associated hSCF in cardiomyocytes under the control of a Tet-off system. 12 We demonstrated that cardiomyocyte-specific hSCF overexpression increased myocardial neovascularization, decreased ventricular remodeling, and increased survival after MI. Our study suggests a novel therapeutic potential of hSCF in the treatment of heart failure after MI.
Methods

Generation of hSCF/Tetracycline Transactivator Double-Transgenic Mice
Animals in this study were handled in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication No. 85-23, revised 1996). A new line of tetracycline-inducible cardiac-specific mice overexpressing hSCF was generated. Briefly, membrane-associated hSCF complementary DNA (accession No. NM_003994) was inserted into the inducible ␣-myosin heavy chain promoter expression vector to permit doxycycline (DOX)-regulated expression in combination with a cardiac-specific tetracycline transactivator (tTA)expressing transgene. The hSCF mice were crossed with cardiacspecific tTA mice previously created 12 to produce wild-type (WT), tTA, hSCF, and hSCF/tTA mice. To turn off hSCF expression, the hSCF/tTA mice were treated with 0.2 mg/mL DOX in their drinking water for 2 weeks before until 5 or 30 days after sham or MI surgery.
Supplemental Methodology
For a detailed explanation of methods relative to generation of hSCF/tTA double-transgenic mice, real-time reverse-transcriptase polymerase chain reaction (RT-PCR), induction of MI, infarct size measurement, 13 histological and hemodynamic analyses, 14, 15 measurements of apoptosis, 16 in vivo matrigel angiogenesis, 15 and statistical analysis, please see the Material section of the online-only Data Supplement.
Results
Generation and Characterization of the Conditional Cardiac-Specific hSCF/tTA Double-Transgenic Mice
hSCF mice were generated with the hSCF transgene expression under the control of a tetracycline-responsive element containing the ␣-myosin heavy chain promoter ( Figure 1A) . The hSCF transgenic mice were then crossed with cardiacspecific tTA mice to generate the inducible cardiac-specific hSCF/tTA double-transgenic mice. The resulting offspring Figure 1 . Generation and characterization of the inducible hSCF/tTA transgenic mouse. A, Illustration of the membrane-associated hSCF transgenic constructs used to create the hSCF transgenic mice. B, Expression of hSCF mRNA was detected in the heart but not in other organs of hSCF/tTA mice in the absence of DOX. C, Cardiac expression of hSCF mRNA in hSCF/tTA mice after treatment with DOX for 5, 10, and 14 days. D, Protein expression of human SCF in heart tissue was measured by Western blotting. Human SCF protein was expressed exclusively in hSCF/tTA-DOX mice. E, Endogenous mouse SCF mRNA expression determined by real-time PCR was not significantly altered among WT, hSCF/tTA-DOX, and hSCF/tTAϩDOX mice. Data are meanϮSEM; nϭ5 to 7 per group. One-way ANOVA followed by Bonferroni test.
were genotyped by PCR with both tTA and hSCF primers. Cardiac-specific expression of hSCF was verified by RT-PCR. Expression of hSCF can be detected in the heart tissue but not in liver, kidney, skin, lung, or skeletal muscle ( Figure  1B ). The inducible expression of hSCF in cardiomyocytes was verified with both RT-PCR and Western blot techniques. Results showed that a high level of hSCF mRNA and protein expression was observed in the hearts of hSCF/tTA mice in the absence of DOX. After 10 to 14 days of continuous DOX administration, the expression of hSCF in hSCF/tTA mice was abrogated at both the mRNA and protein levels ( Figure  1C and 1D). Transgene expression did not affect endogenous mouse SCF expression because myocardial mouse SCF mRNA levels analyzed with real-time RT-PCR were similar among WT, hSCF/tTA-DOX, and hSCF/tTAϩDOX mice ( Figure 1E ). Furthermore, there were no coat color changes in any of the hSCF/tTA mice.
Post-MI SCF Expression
A total of 87 hSCF/tTA mice and 105 littermates (tTA, hSCF, and WT) were subjected to coronary artery ligation or sham operation. General characteristics of these animals are shown in Table 1 . There were no statistical differences in age, sex, or body weight between hSCF/tTA mice and littermates in the sham or MI groups (PϭNS). Protein expression of mouse SCF after MI was studied by Western blot analysis in WT mice. Myocardial mouse SCF protein levels were significantly decreased at 5 days (PϽ0.05; Figure 2A ) but not at 30 days (PϭNS; Figure 2B ) after MI compared with the sham group. The expression of hSCF as determined by real-time RT-PCR in hSCF/tTA mice was unchanged in the peri-infarct area at 5 days ( Figure 2C ) and 30 days ( Figure 2D ) after MI compared with shams.
Survival and Cardiac Function After MI
Postoperation survival was monitored for 30 days in the WT and hSCF/tTA sham groups and in the WT and hSCF/tTA MI groups (nϭ13, 11, 37, and 34, respectively). Survival of the sham groups was 100%. MI resulted in significantly lower survival compared with the sham groups (PϽ0.05). However, the 30-day survival of hSCF/tTA MI mice was significantly higher compared with WT mice (85% versus 54%; PϽ0.01; Figure 3A ).
To evaluate the effect of cardiac-specific hSCF expression on cardiac function, LV hemodynamic parameters were analyzed by a pressure-volume analysis system 5 and 30 days after MI. There was no significant difference in heart rate, mean arterial pressure, or cardiac output between hSCF/tTA and littermate controls (Tables 2 and 3 ). Five days after MI, cardiac function of WT MI mice as determined by LV dP/dt, ϪdP/dt, and preload-adjusted maximum power was significantly decreased compared with sham groups (PϽ0.05, Figure 3B ). In the absence of DOX, which expresses hSCF, LV dP/dt, ϪdP/dt, and preload-adjusted maximum power were significantly restored in hSCF/tTA MI mice (hSCF/tTA MI versus WT MI, PϽ0.05; Figure 3B ). The increase in cardiac function was completely blocked by DOX treatment, which turned off hSCF expression (hSCF/tTAϩDOX MI Data are meanϮSEM and analyzed by 2-way ANOVA with Bonferroni test for age, sex, and body weight. Infarct size was compared by Student t test. There was no statistical difference between control and hSCF/tTA mice in any of the parameters listed within the sham or MI groups. Controls include WT, tTA, and hSCF mice. Total number of animals includes all 5-and 30-day groups and the DOX treatment groups.
Figure 2.
Mouse SCF expression in the heart after MI. Myocardial mouse SCF protein levels at 5 days (A) and 30 days (B) after MI were measured by Western blot analysis in WT mice. Compared with the sham group, mouse SCF protein levels were significantly decreased at 5 but not 30 days after MI. hSCF mRNA expression was detected in hSCF/tTA mice at 5 days (C) and 30 days (D) after MI by real-time RT-PCR. There was no significant change in cardiac hSCF expression in hSCF/tTA mice after MI. Data are meanϮSEM; nϭ4 to 5 per group. One-way ANOVA followed by Bonferroni test: *PϽ0.05 vs sham.
versus hSCF/tTA MI, PϽ0.05; Figure 3B ). Thirty days after surgery, LV dP/dt, ϪdP/dt, and ejection fraction were significantly decreased in WT, tTA, and hSCF MI groups compared with WT shams (PϽ0.05; Figure 3C and 3D). Overexpression of hSCF significantly improved cardiac function (hSCF/tTA MI versus WT, tTA, and hSCF MI groups, PϽ0.05; Figure 3C and 3D). Furthermore, LV end-diastolic volume was significantly increased in the WT, tTA, and hSCF MI groups compared with WT shams but significantly decreased in hSCF/tTA MI mice compared with other MI groups (PϽ0.05; Figure 3D ). However, the improvement in cardiac function in hSCF/tTA mice 30 days after MI was abrogated after DOX treatment ( Figure 3C and 3D).
Myocardial Apoptosis 5 Days After MI
To investigate mechanisms responsible for the improvement in cardiac function by cardiac-specific hSCF overexpression, myocardial apoptosis in the peri-infarct area was studied 5 days after MI. Myocardial apoptosis was determined by caspase-3 activity and cell-death ELISA. Both caspase-3 activity and cytosolic DNA fragments were significantly increased in the WT MI group compared with the sham group (PϽ0.05), whereas these indexes were significantly decreased in the hSCF/tTA MI mice compared with the WT MI group (PϽ0.05; Figure 4A and 4B). The decrease in apoptosis was abrogated in the hSCF/tTAϩDOX MI group in which the expression of hSCF was turned off (PϽ0.05; Figure 4A and 4B).
Stem Cell Recruitment and Growth Factor Release After MI
Stem cell recruitment to the peri-infarct area of the myocardium was evaluated by c-kit and c-kit/vascular endothelial growth factor (VEGF) receptor 2 (VEGFR2) double staining. Because VEGFR2 is an important marker for endothelial progenitor cells (EPCs), cells positive for c-kit/VEGFR2 are likely EPCs. Representative fluorescent photomicrographs at 5 and 30 days after MI are shown in Figure 5A and 5C. Quantitative analysis showed that there were significantly more c-kit ϩ and c-kit ϩ /VEGFR2 ϩ cells retained in the periinfarct area in hSCF/tTA compared with WT mice 5 days after MI (PϽ0.05; Figure 5C ). Treatment with DOX, which turns off hSCF expression, abrogated the recruitment of c-kit ϩ and c-kit ϩ /VEGFR2 ϩ cells (PϽ0.05; Figure 5C ). Interestingly, 80% of the cells were c-kit ϩ /VEGFR2 ϩ , indicating that the majority of stem cells are EPCs. Furthermore, capillaries in the peri-infarct area were positive for c-kit and VEGFR2 in the hSCF/tTA mice ( Figure 5A , third panel), suggesting incorporation of EPCs into the newly formed vessels. At 30 days after MI, myocardial stem cell density in the peri-infarct area was decreased to similar low levels in both WT and hSCF/tTA mice ( Figure 5C and 5D ).
Mast cells also express c-kit. To analyze myocardial mast cell density, heart sections were stained with toluidine blue. Consistent with previous studies, there were very few mast cells in shams or infarct myocardium in WT mice, 17 and no significant increase in mast cells was observed in hSCF/tTA mice at either 5 or 30 days after MI (see Table I and Figure  I of the online-only Data Supplement). Thus, the influence of mast cells on c-kit ϩ stem cell analysis in the infarct myocardium is negligible in the present study.
Previous studies have implicated growth factors, including VEGF-A, insulin growth factor-1, and basic fibroblast growth factor, in cardiac repair after MI. 18 To determine the expression of these growth factors, real-time RT-PCR was used. The mRNA levels of VEGF-A, insulin growth factor-1, and basic fibroblast growth factor in the peri-infarct area 5 days after MI were significantly increased in hSCF/tTA compared with WT mice (PϽ0.05; Figure 5E ).
LV Hypertrophy 30 Days After MI
The ratio of LV weight to body weight, a measure of LV hypertrophy, was similar between sham groups but was significantly increased in WT MI mice compared with WT shams (PϽ0.05; Figure 6A ). However, the ratio in hSCF/tTA MI mice was significantly decreased compared with WT MI mice (PϽ0.05, Figure 6A ). MI-induced LV hypertrophy was further studied at the cellular level by histological analysis. Representative photomicrographs of hematoxylin and eosin stained sections are shown in Figure 6B . Myocyte transverse diameters were assessed using the minimum cross-sectional diameter at the nuclear level to reduce the effects of myocyte orientation on cell size measurements. 19 The minimum crosssectional diameter was similar between sham groups but was significantly increased in the WT MI compared with WT sham mice (PϽ0.05; Figure 6C ). However, the hSCF/tTA MI mice showed significantly smaller myocyte cross-sectional diameters compared with those of WT MI mice (PϽ0.05; Figure 6C ). Furthermore, these effects were abrogated when hSCF expression was turned off by DOX treatment ( Figure  6A and 6C ).
Capillary Density After MI
To quantify myocardial capillary density, lectin-⌱ staining was used to specifically stain endothelial cells. Representative photomicrographs of lectin-⌱ staining are presented in Figure 7A (5 days after MI) and Figure 7C (30 days after MI). In mice 5 days after surgery, myocardial capillary density was similar between WT and hSCF/tTA sham mice ( Figure  7B ). The capillary density in the peri-infarct area of the MI group was significantly decreased compared with the sham groups (PϽ0.05; Figure 7B ). When hSCF expression was activated in the hSCF/tTA mice in the absence of DOX, capillary density was significantly increased (hSCF/tTA MI versus WT MI, PϽ0.05; Figure 7B ). However, the increase was abrogated by DOX treatment in hSCF/tTA mice (hSCF/tTAϩDOX MI versus hSCF/tTA MI, PϽ0.05; Figure 7B ). Capillary density also was assessed 30 days after surgery. Myocardial capillary density was similar between WT and hSCF/tTA sham mice ( Figure 7D ). Capillary density in the peri-infarct area of the MI groups was significantly decreased compared with the respective sham groups (PϽ0.05; Figure 7D ). Overexpression of hSCF significantly increased capillary density (hSCF/tTA MI versus WT MI, PϽ0.05; Figure 7D ). DOX treatment abrogated the increase in capillary density in hSCF/tTA mice ( Figure 7D ).
In Vivo Myocardial Angiogenesis
The ability of the hSCF expressed in the cardiomyocytes to promote angiogenesis was investigated in vivo by implanting matrigel into the LV myocardium for 3 days. As shown in Figure 8A , the matrigel was surrounded by inflammatory cells and could be easily identified in the myocardium. The newly formed vessels that penetrated into the gel plug showed aneurysm-like structures inside the gel. The area of capillaries and aneurysm-like structures penetrating the matrigel plug was quantified in relation to the total matrigel area. The percentage of vessel-like areas was significantly increased in hSCF/tTA compared with WT mice (PϽ0.05; Figure 8B ). 
Discussion
The present study demonstrates for the first time that cardiomyocyte-specific expression of membrane-associated hSCF improves survival and cardiac function after MI. The beneficial effects of transgene expression are associated with reduced myocardial apoptosis, increased recruitment of stem cells to the infarcted myocardium, enhanced myocardial neovascularization, and attenuated ventricular remodeling. The improvements in cardiac function and myocardial angiogenesis are a result of hSCF overexpression because treatment with DOX, which turns off hSCF expression, abrogates these effects after MI. Our study suggests that hSCF may have therapeutic potential in the treatment of heart failure after MI.
C-kit signaling can promote cardiac repair after MI. Administration of c-kit ϩ stem cells, whether through intravenous injection or local delivery into the infarcted myocardium after MI, improves cardiac function, enhances angiogenesis, and impairs cardiac remodeling. 20, 21 On the other hand, c-kitdeficient (W/W v ) mice exhibit dilated cardiomyopathy after MI. After replacement with normal WT bone marrow, the cardiomyopathic phenotype of W/W v mice is rescued. 22, 23 However, the W/W v mice have defects in hematopoietic stem cell function, abnormal islet ␤-cell development, and impaired glucose tolerance. 24, 25 These abnormalities also likely contribute to the impaired cardiac repair after MI. As the ligand of c-kit, soluble SCF is increased in the bone marrow after myocardial ischemia/reperfusion injury, leading to EPC mobilization and improvement in myocardial neovascularization and cardiac function. 26 Furthermore, peri-infarct injections of soluble SCF increased c-kit ϩ stem cell recruitment to the infarcted heart after intravenous administration of bone marrow-derived stem cells. 27 Although this effect lasted 72 hours, no functional benefit was observed.
After MI, circulating c-kit ϩ bone marrow stem cells and EPCs are increased. 28 -30 However, stem cell attractants SDF-1 and SCF, and proangiogenic genes such as VEGF-A and VEGFR2 are decreased in the infarct region after MI. 8 The stem/progenitor cells mobilized into the peripheral blood may not be recruited in sufficient numbers or retained in the infarcted myocardium to participate in cardiac repair because of decreased myocardial expression of stem cell attractants such as SCF. 8 To increase the recruitment and retention of stem/progenitor cells in the infarcted myocardium and to improve cardiac repair after MI, we generated a cardiomyocyte-specific membrane-associated hSCF-overexpressing mouse. Although our findings imply enhanced signaling, endogenous SCF expression and signaling were previously found to be reduced in mice strongly overexpressing hSCF starting from embryonic development in multiple tissues under the control of human phosphoglycerate kinase promoter. 31 This was interpreted as evidence that hSCF antagonizes mouse SCF signaling. 31 However, studies have shown that hSCF behaves as a full agonist at mouse c-kit. 32, 33 It follows that strong hSCF overexpression may desensitize and/or downregulate Ն1 key components of mouse c-kit signaling, consistent with the observed loss of endogenous SCF. 31 Our mouse model differs from the one in the previous study in that a relatively weak cardiac-specific promoter was used to induce hSCF expression only postnatally, and thus endogenous mouse SCF downregulation and "functional antagonism" were not observed.
Our data showed that cardiac-specific overexpression of hSCF promoted EPC recruitment to the infarcted myocardium. Importantly, these cells participated in the angiogenic process in that they were incorporated into the newly formed vessels in the infarcted myocardium. Consistent with this hypothesis, myocardial capillary density was increased in the hSCFoverexpressing mice after MI. In addition, c-kit signaling can increase cell survival and stem cell function. 34, 35 Thus, although the absolute number of stem cells retained in the infarcted myocardium is only doubled by hSCF overexpression, it is possible that the improvement in survival and functional capacity of these stem cells could result in the increased release of soluble factors, causing beneficial paracrine actions in the myocardium. 18 In support of this paracrine hypothesis, expression of several candidate mediators such as VEGF-A, basic fibroblast growth factor, and insulin growth factor-1 was increased in the myocardium overexpressing membrane-associated hSCF after MI. Indeed, hSCF overexpression decreases myocardial apoptosis and cardiac hypertrophy, leading to improvement in cardiac function and survival after MI.
Effects of SCF on cardiac function also have been studied through the use of cardiac transplantation of mesenchymal stem cells transfected with a full-length mouse SCF complementary DNA plasmid expressing both soluble and membrane-associated SCF. 36 Transplantation of mesenchymal stem cells containing SCF plasmids enhanced EPC recruitment and myocardial angiogenesis after MI for Ϸ2 weeks. However, there was no change in animal survival among all treatment groups. Furthermore, cardiac function determined at 4 weeks after MI was not significantly improved by SCF transfection compared with the mesenchymal stem cell group. 36 This is not surprising because Ͼ95% of the transplanted mesenchymal stem cells are cleared within 7 days after transplantation into the myocardium. 37 In the present study, to study the long-term effects of SCF on the infarcted myocardium, we chose to express the membraneassociated isoform of hSCF specifically in the heart. hSCF expressed on the membrane of cardiomyocytes serves as a chemoattractant for circulating stem cells to migrate to and stay in the myocardium. hSCF expression was stable and sustained over the entire study period. Furthermore, the Tet-off system used allowed reversible cardiac expression of hSCF. In this regard, treatment with DOX turned off hSCF expression and reversed the beneficial effects of hSCF in mice with MI. Our data showed that cardiomyocyte-specific hSCF overexpression promoted angiogenesis, increased capillary density, decreased myocardial apoptosis, and reduced LV hypertrophy after MI. These beneficial effects led to significant improvements in cardiac function and survival in hSCF/tTA mice after MI and are likely due to the enhanced recruitment and retention of EPCs to the infarct myocardium and improved cardiac repair. Cardiac regeneration via transdifferentiation from bone marrow stem cells in vivo after MI is still debatable. 20 Whether hSCF overexpression promotes
